An antiendothelial combination therapy strategy to increase survival in experimental pancreatic cancer

Surgery

Volumn 146, Issue 2, 2009, Pages 241-249

  Schwarz, Roderich E ^a,b   Konduri, Srivani ^b   Awasthi, Niranjan ^a,b   Cafasso, Danielle ^b   Schwarz, Margaret A ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIAL MONOCYTE ACTIVATING POLYPEPTIDE II; GEMCITABINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; TREATMENT OUTCOME;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOKINES; DEOXYCYTIDINE; FEMALE; HUMANS; MICE; MICE, NUDE; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; PANCREATIC NEOPLASMS; RNA-BINDING PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 67650665789     PISSN: 00396060     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.surg.2009.04.015     Document Type: Article

References (25)

1. Jemal A., Siegel R., Ward E., Murray T., Xu J., and Thun M.J. Cancer statistics, 2007. CA Cancer J Clin 57 (2007) 43-66
2. Greenlee R.T., Murray T., Bolden S., and Wingo P.A. Cancer statistics, 2000. CA Cancer J Clin 50 (2000) 7-33
3. Rocha-Lima C.M. New directions in the management of advanced pancreatic cancer: a review. Anticancer Drugs 19 (2008) 435-446
4. Berlin J.D., Catalano P., Thomas J.P., Kugler J.W., Haller D.G., and Benson III A.B. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 20 (2002) 3270-3275
5. Louvet C., Labianca R., Hammel P., Lledo G., Zampino M.G., Andre T., et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 23 (2005) 3509-3516
6. Rocha Lima C.M., Green M.R., Rotche R., Miller Jr. W.H., Jeffrey G.M., Cisar L.A., et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 22 (2004) 3776-3783
7. Bramhall S.R., Schulz J., Nemunaitis J., Brown P.D., Baillet M., and Buckels J.A. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer 87 (2002) 161-167
8. Longo R., Cacciamani F., Naso G., and Gasparini G. Pancreatic cancer: from molecular signature to target therapy. Crit Rev Oncol Hematol 68 (2008) 197-211
9. Dragovich T., Burris III H., Loehrer P., Von Hoff D.D., Chow S., Stratton S., et al. Gemcitabine plus celecoxib in patients with advanced or metastatic pancreatic adenocarcinoma: results of a phase II trial. Am J Clin Oncol 31 (2008) 157-162
10. Heinemann V., Quietzsch D., Gieseler F., Gonnermann M., Schonekas H., Rost A., et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 24 (2006) 3946-3952
11. Ko A.H., Dito E., Schillinger B., Venook A.P., Xu Z., Bergsland E.K., et al. A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable?. Invest New Drugs 26 (2008) 463-471
12. Schwarz M.A., Kandel J., Brett J., Li J., Hayward J., Schwarz R.E., et al. Endothelial-monocyte activating polypeptide II, a novel antitumor cytokine that suppresses primary and metastatic tumor growth and induces apoptosis in growing endothelial cells. J Exp Med 190 (1999) 341-354
13. Schwarz R.E., and Schwarz M.A. In vivo therapy of local tumor progression by targeting vascular endothelium with EMAP-II. J Surg Res 120 (2004) 64-72
14. Awasthi N., Schwarz M.A., Verma V., Cappiello C., and Schwarz R.E. Endothelial monocyte activating polypeptide II interferes with VEGF-induced proangiogenic signaling. Lab Invest 89 (2000) 38-46
15. Schwarz M.A., Zhang F., Gebb S., Starnes V., and Warburton D. Endothelial monocyte activating polypeptide II inhibits lung neovascularization and airway epithelial morphogenesis. Mech Dev 95 (2000) 123-132
16. Schwarz R.E., Donohue C.A., Sadava D., and Kane S.E. Pancreatic cancer in vitro toxicity mediated by Chinese herbs SPES and PC-SPES: implications for monotherapy and combination treatment. Cancer Lett 189 (2003) 59-68
17. Schwarz R.E., McCarty T.M., Peralta E.A., Diamond D.J., and Ellenhorn J.D. An orthotopic in vivo model of human pancreatic cancer. Surgery 126 (1999) 562-567
18. Abbruzzese J.L. New applications of gemcitabine and future directions in the management of pancreatic cancer. Cancer 95 (2002) 941-945
19. Burris III H.A., Moore M.J., Andersen J., Green M.R., Rothenberg M.L., Modiano M.R., et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15 (1997) 2403-2413
20. Moore M.J., Goldstein D., Hamm J., Figer A., Hecht J.R., Gallinger S., et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25 (2007) 1960-1966
21. Schwarz R, Konduri S, Awasthi N, Caldwell L, Cafasso D, Schwarz M. Inhibition of fibronectin-dependent pancreatic cancer proliferation through EMAP II therapy. In press.
22. Schwarz M.A., Zheng H., Liu J., Corbett S., and Schwarz R.E. Endothelial-monocyte activating polypeptide II alters fibronectin based endothelial cell adhesion and matrix assembly via alpha5 beta1 integrin. Exp Cell Res 311 (2005) 229-239
23. Semenza G.L. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3 (2003) 721-732
24. Berger A.C., Alexander H.R., Tang G., Wu P.S., Hewitt S.M., Turner E., et al. Endothelial monocyte activating polypeptide II induces endothelial cell apoptosis and may inhibit tumor angiogenesis. Microvasc Res 60 (2000) 70-80
25. Heldin C.H., Rubin K., Pietras K., and Ostman A. High interstitial fluid pressure-an obstacle in cancer therapy. Nat Rev Cancer 4 (2004) 806-813